Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders—Crohn’s disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, inflixi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/9/1766 |
| _version_ | 1797483699983351808 |
|---|---|
| author | Zvonimir Petric Joao Goncalves Paulo Paixao |
| author_facet | Zvonimir Petric Joao Goncalves Paulo Paixao |
| author_sort | Zvonimir Petric |
| collection | DOAJ |
| description | Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders—Crohn’s disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, infliximab (IFX) and adalimumab (ADL), transformed the pharmacological approach of treating CD and UC. However, due to the complex interplay of pharmacology and immunology, MAbs face challenges related to their immunogenicity, effectiveness, and safety. To ease the burden of IBD and other severe diseases, biosimilars have emerged as a cost-effective alternative to an originator product. According to the current knowledge, biosimilars of IFX and ADL in IBD patients are shown to be as safe and effective as their originators. The future of biosimilars, in general, is promising due to the potential of making the health care system more sustainable. However, their use is accompanied by misconceptions regarding their effectiveness and safety, as well as by controversy regarding their interchangeability. Hence, until a scientific consensus is achieved, scientific data on the long-term effectiveness and safety of biosimilars are needed. |
| first_indexed | 2024-03-09T22:51:47Z |
| format | Article |
| id | doaj.art-e5bbba56e8744379804a0dffe74ecd75 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T22:51:47Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-e5bbba56e8744379804a0dffe74ecd752023-11-23T18:20:07ZengMDPI AGPharmaceutics1999-49232022-08-01149176610.3390/pharmaceutics14091766Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of BiosimilarsZvonimir Petric0Joao Goncalves1Paulo Paixao2Department of Pharmacological Sciences, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, PortugalBiopharmaceutical and Molecular Biotechnology Unit, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, PortugalDepartment of Pharmacological Sciences, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, PortugalMonoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders—Crohn’s disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, infliximab (IFX) and adalimumab (ADL), transformed the pharmacological approach of treating CD and UC. However, due to the complex interplay of pharmacology and immunology, MAbs face challenges related to their immunogenicity, effectiveness, and safety. To ease the burden of IBD and other severe diseases, biosimilars have emerged as a cost-effective alternative to an originator product. According to the current knowledge, biosimilars of IFX and ADL in IBD patients are shown to be as safe and effective as their originators. The future of biosimilars, in general, is promising due to the potential of making the health care system more sustainable. However, their use is accompanied by misconceptions regarding their effectiveness and safety, as well as by controversy regarding their interchangeability. Hence, until a scientific consensus is achieved, scientific data on the long-term effectiveness and safety of biosimilars are needed.https://www.mdpi.com/1999-4923/14/9/1766monoclonal antibodiesinflammatory bowel diseaseanti-TNF-α agentsinfliximab (IFX)adalimumab (ADL)immunogenicity |
| spellingShingle | Zvonimir Petric Joao Goncalves Paulo Paixao Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars Pharmaceutics monoclonal antibodies inflammatory bowel disease anti-TNF-α agents infliximab (IFX) adalimumab (ADL) immunogenicity |
| title | Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars |
| title_full | Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars |
| title_fullStr | Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars |
| title_full_unstemmed | Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars |
| title_short | Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars |
| title_sort | under the umbrella of clinical pharmacology inflammatory bowel disease infliximab and adalimumab and a bridge to an era of biosimilars |
| topic | monoclonal antibodies inflammatory bowel disease anti-TNF-α agents infliximab (IFX) adalimumab (ADL) immunogenicity |
| url | https://www.mdpi.com/1999-4923/14/9/1766 |
| work_keys_str_mv | AT zvonimirpetric undertheumbrellaofclinicalpharmacologyinflammatoryboweldiseaseinfliximabandadalimumabandabridgetoaneraofbiosimilars AT joaogoncalves undertheumbrellaofclinicalpharmacologyinflammatoryboweldiseaseinfliximabandadalimumabandabridgetoaneraofbiosimilars AT paulopaixao undertheumbrellaofclinicalpharmacologyinflammatoryboweldiseaseinfliximabandadalimumabandabridgetoaneraofbiosimilars |